Chronomodulated drug delivery system of Irbesartan: Formulation and development using Desing of Experiment (DoE)

The work is based on pulsatile principles to deliver a programmed dose of Irbesartan, an angiotensin-II receptor antagonist for chronotherapy of hypertension induced by excessive secretion of aldosterone, thereby lower the blood pressure at early morning. Solid dispersion of Irbesartan, a BCS class...

Full description

Bibliographic Details
Main Authors: Komal Parmar, Almas Shaikh, Hitesh Dalvadi
Format: Article
Language:English
Published: Faculty of Pharmacy, Cairo University 2018-06-01
Series:Bulletin of Faculty of Pharmacy Cairo University
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1110093117300649
_version_ 1797965464075239424
author Komal Parmar
Almas Shaikh
Hitesh Dalvadi
author_facet Komal Parmar
Almas Shaikh
Hitesh Dalvadi
author_sort Komal Parmar
collection DOAJ
description The work is based on pulsatile principles to deliver a programmed dose of Irbesartan, an angiotensin-II receptor antagonist for chronotherapy of hypertension induced by excessive secretion of aldosterone, thereby lower the blood pressure at early morning. Solid dispersion of Irbesartan, a BCS class II drug, was prepared by using Poloxamer-188 by melt method in ratio of 1:1 to increase the dissolution properties of drug. Compressed coated pulsatile tablets included a core layer consisting of Kyron T-134 as a super-disintegrant and pulsatile layer comprising of HPMC K4M and Eudragit RLPO. The prepared core tablets were evaluated for weight variation, hardness, thickness, friability, drug content, disintegration time and In vitro dissolution studies. Final core tablet (C8) was selected on the basis of disintegration time (23.33 ± 2.08 s). For optimization Face centred central composite design was employed to study the effect of independent variables viz. Weight ratio of HPMC K4M: Eudragit RLPO (X1) and Total weight of coating (X2) on dependent variables viz. Drug release lag time (Y1) and Drug release after lag time within 15 min (D15) (Y2). Results revealed positive influence of independent factors on responses. The data were statistically analyzed using ANOVA and were found to be statistically significant (P < .05). Mathematical modeling for kinetic studies revealed that the release profile after lag time followed first order kinetics. Accelerated stability studies for one month at 40 ± 2 °C/75 ± 5% RH showed no remarkable changes concluding that a successful pulsatile drug delivery system of Irbesartan was developed.
first_indexed 2024-04-11T02:00:21Z
format Article
id doaj.art-1388b01a497f4b55ab835006c16ff006
institution Directory Open Access Journal
issn 1110-0931
language English
last_indexed 2024-04-11T02:00:21Z
publishDate 2018-06-01
publisher Faculty of Pharmacy, Cairo University
record_format Article
series Bulletin of Faculty of Pharmacy Cairo University
spelling doaj.art-1388b01a497f4b55ab835006c16ff0062023-01-03T04:15:18ZengFaculty of Pharmacy, Cairo UniversityBulletin of Faculty of Pharmacy Cairo University1110-09312018-06-01561111710.1016/j.bfopcu.2017.11.004Chronomodulated drug delivery system of Irbesartan: Formulation and development using Desing of Experiment (DoE)Komal ParmarAlmas ShaikhHitesh DalvadiThe work is based on pulsatile principles to deliver a programmed dose of Irbesartan, an angiotensin-II receptor antagonist for chronotherapy of hypertension induced by excessive secretion of aldosterone, thereby lower the blood pressure at early morning. Solid dispersion of Irbesartan, a BCS class II drug, was prepared by using Poloxamer-188 by melt method in ratio of 1:1 to increase the dissolution properties of drug. Compressed coated pulsatile tablets included a core layer consisting of Kyron T-134 as a super-disintegrant and pulsatile layer comprising of HPMC K4M and Eudragit RLPO. The prepared core tablets were evaluated for weight variation, hardness, thickness, friability, drug content, disintegration time and In vitro dissolution studies. Final core tablet (C8) was selected on the basis of disintegration time (23.33 ± 2.08 s). For optimization Face centred central composite design was employed to study the effect of independent variables viz. Weight ratio of HPMC K4M: Eudragit RLPO (X1) and Total weight of coating (X2) on dependent variables viz. Drug release lag time (Y1) and Drug release after lag time within 15 min (D15) (Y2). Results revealed positive influence of independent factors on responses. The data were statistically analyzed using ANOVA and were found to be statistically significant (P < .05). Mathematical modeling for kinetic studies revealed that the release profile after lag time followed first order kinetics. Accelerated stability studies for one month at 40 ± 2 °C/75 ± 5% RH showed no remarkable changes concluding that a successful pulsatile drug delivery system of Irbesartan was developed.http://www.sciencedirect.com/science/article/pii/S1110093117300649IrbesartanPulsatileHPMC K4MEudragit RLPOLag time
spellingShingle Komal Parmar
Almas Shaikh
Hitesh Dalvadi
Chronomodulated drug delivery system of Irbesartan: Formulation and development using Desing of Experiment (DoE)
Bulletin of Faculty of Pharmacy Cairo University
Irbesartan
Pulsatile
HPMC K4M
Eudragit RLPO
Lag time
title Chronomodulated drug delivery system of Irbesartan: Formulation and development using Desing of Experiment (DoE)
title_full Chronomodulated drug delivery system of Irbesartan: Formulation and development using Desing of Experiment (DoE)
title_fullStr Chronomodulated drug delivery system of Irbesartan: Formulation and development using Desing of Experiment (DoE)
title_full_unstemmed Chronomodulated drug delivery system of Irbesartan: Formulation and development using Desing of Experiment (DoE)
title_short Chronomodulated drug delivery system of Irbesartan: Formulation and development using Desing of Experiment (DoE)
title_sort chronomodulated drug delivery system of irbesartan formulation and development using desing of experiment doe
topic Irbesartan
Pulsatile
HPMC K4M
Eudragit RLPO
Lag time
url http://www.sciencedirect.com/science/article/pii/S1110093117300649
work_keys_str_mv AT komalparmar chronomodulateddrugdeliverysystemofirbesartanformulationanddevelopmentusingdesingofexperimentdoe
AT almasshaikh chronomodulateddrugdeliverysystemofirbesartanformulationanddevelopmentusingdesingofexperimentdoe
AT hiteshdalvadi chronomodulateddrugdeliverysystemofirbesartanformulationanddevelopmentusingdesingofexperimentdoe